JP2021500857A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500857A5
JP2021500857A5 JP2020516389A JP2020516389A JP2021500857A5 JP 2021500857 A5 JP2021500857 A5 JP 2021500857A5 JP 2020516389 A JP2020516389 A JP 2020516389A JP 2020516389 A JP2020516389 A JP 2020516389A JP 2021500857 A5 JP2021500857 A5 JP 2021500857A5
Authority
JP
Japan
Prior art keywords
polypeptide
item
amino acid
seq
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500857A (ja
JP7854267B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/053747 external-priority patent/WO2019070577A1/en
Publication of JP2021500857A publication Critical patent/JP2021500857A/ja
Publication of JP2021500857A5 publication Critical patent/JP2021500857A5/ja
Priority to JP2023171561A priority Critical patent/JP2023179600A/ja
Priority to JP2026018468A priority patent/JP2026077678A/ja
Application granted granted Critical
Publication of JP7854267B2 publication Critical patent/JP7854267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516389A 2017-10-02 2018-10-01 酵素補充療法用酵素を含む融合タンパク質 Active JP7854267B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023171561A JP2023179600A (ja) 2017-10-02 2023-10-02 酵素補充療法用酵素を含む融合タンパク質
JP2026018468A JP2026077678A (ja) 2017-10-02 2026-02-06 酵素補充療法用酵素を含む融合タンパク質

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762566898P 2017-10-02 2017-10-02
US62/566,898 2017-10-02
US201762583276P 2017-11-08 2017-11-08
US62/583,276 2017-11-08
US201862626365P 2018-02-05 2018-02-05
US62/626,365 2018-02-05
US201862678183P 2018-05-30 2018-05-30
US62/678,183 2018-05-30
US201862721396P 2018-08-22 2018-08-22
US62/721,396 2018-08-22
PCT/US2018/053747 WO2019070577A1 (en) 2017-10-02 2018-10-01 FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023171561A Division JP2023179600A (ja) 2017-10-02 2023-10-02 酵素補充療法用酵素を含む融合タンパク質
JP2026018468A Division JP2026077678A (ja) 2017-10-02 2026-02-06 酵素補充療法用酵素を含む融合タンパク質

Publications (3)

Publication Number Publication Date
JP2021500857A JP2021500857A (ja) 2021-01-14
JP2021500857A5 true JP2021500857A5 (cg-RX-API-DMAC7.html) 2021-11-04
JP7854267B2 JP7854267B2 (ja) 2026-05-01

Family

ID=64267892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516389A Active JP7854267B2 (ja) 2017-10-02 2018-10-01 酵素補充療法用酵素を含む融合タンパク質
JP2023171561A Pending JP2023179600A (ja) 2017-10-02 2023-10-02 酵素補充療法用酵素を含む融合タンパク質
JP2026018468A Pending JP2026077678A (ja) 2017-10-02 2026-02-06 酵素補充療法用酵素を含む融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023171561A Pending JP2023179600A (ja) 2017-10-02 2023-10-02 酵素補充療法用酵素を含む融合タンパク質
JP2026018468A Pending JP2026077678A (ja) 2017-10-02 2026-02-06 酵素補充療法用酵素を含む融合タンパク質

Country Status (20)

Country Link
US (3) US20200277584A1 (cg-RX-API-DMAC7.html)
EP (2) EP3692070A1 (cg-RX-API-DMAC7.html)
JP (3) JP7854267B2 (cg-RX-API-DMAC7.html)
KR (1) KR102997172B1 (cg-RX-API-DMAC7.html)
CN (2) CN121780481A (cg-RX-API-DMAC7.html)
AU (2) AU2018345303B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020005271A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076369A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000810A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020003128A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200129A (cg-RX-API-DMAC7.html)
IL (1) IL273439B2 (cg-RX-API-DMAC7.html)
MA (1) MA50746A (cg-RX-API-DMAC7.html)
MX (3) MX2020002918A (cg-RX-API-DMAC7.html)
MY (1) MY209029A (cg-RX-API-DMAC7.html)
PE (1) PE20210347A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550510A1 (cg-RX-API-DMAC7.html)
SA (1) SA520411662B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002730XA (cg-RX-API-DMAC7.html)
WO (1) WO2019070577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3894864A2 (en) 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) * 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
CN110111326B (zh) * 2019-05-15 2021-01-15 西安科技大学 基于ert系统的重建图像质量评价方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021158986A1 (en) * 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CR20230178A (es) * 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
KR20220073454A (ko) * 2020-11-26 2022-06-03 한미약품 주식회사 신규한 뇌 표적 지속형 단백질 결합체 및 이의 제조방법
MA71665A (fr) 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
US20250018015A1 (en) 2021-07-23 2025-01-16 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
AR128003A1 (es) 2021-12-17 2024-03-20 Denali Therapeutics Inc PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS
WO2023198661A1 (en) * 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
WO2023244540A1 (en) 2022-06-13 2023-12-21 Denali Therapeutics Inc. A quantitative pharmacological model of enzyme replacement therapy
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用
WO2024211624A1 (en) * 2023-04-04 2024-10-10 University Of Cincinnati Novel treatment strategies for pancreatic cancer using recombinant acid sphingomyelinase
EP4698671A2 (en) 2023-04-21 2026-02-25 Denali Therapeutics Inc. Methods of increasing sialic acid levels in recombinant glycosylated proteins
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2025166045A1 (en) * 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
TW202617982A (zh) 2024-06-24 2026-05-01 美商戴納立製藥公司 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法
CN121652292A (zh) * 2025-12-31 2026-03-13 中山圣湘海济生物医药有限公司 Fc-hGH融合蛋白、编码核酸、载体、工程细胞及其构建与制备方法和应用

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
US7871624B2 (en) * 2006-06-27 2011-01-18 Saint Louis University Chimeral polypeptide composition for cross-placenta delivery
WO2008105796A2 (en) 2006-06-29 2008-09-04 Albert Einstein College Of Medicine Of Yeshiva University Compounds and methods for detecting ricin and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
JP6131190B2 (ja) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド リン酸化n−グリカンの脱マンノシル化
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
JP5913122B2 (ja) 2010-11-08 2016-04-27 Jcrファーマ株式会社 新規発現ベクター
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US9206401B2 (en) 2010-12-22 2015-12-08 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
LT2714752T (lt) 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
CN104145015A (zh) 2011-12-01 2014-11-12 安吉奥开米公司 靶向的溶酶体酶化合物
US20140335163A1 (en) 2011-12-01 2014-11-13 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US9682129B2 (en) 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
BR112014024358A8 (pt) 2012-03-30 2018-01-23 Shire Human Genetic Therapies administração subcutânea de iduronato-2-sulfatase
JP5855239B2 (ja) 2012-04-23 2016-02-09 株式会社Nrlファーマ ラクトフェリン融合タンパク質及びその製造方法
JP6279466B2 (ja) 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US20130323221A1 (en) 2012-05-30 2013-12-05 Biostrategies LC Plant lectins as carriers of associated drug substances into animal and human cells
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2013185235A1 (en) 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US10138474B2 (en) 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
WO2014082080A2 (en) 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
CN104955946A (zh) 2012-11-30 2015-09-30 安吉奥开米公司 靶向的艾杜糖醛酸-2-硫酸酯酶化合物
CN105027138B (zh) 2012-12-27 2018-01-26 施耐德电气It公司 可视化气流的系统和方法
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
WO2014194427A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted iduronate-2-sulfatase fusion proteins
MX370570B (es) 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
US20150023956A1 (en) 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
JP6309427B2 (ja) 2013-10-09 2018-04-11 Jcrファーマ株式会社 イズロン酸−2−スルファターゼの活性測定法
JP6616189B2 (ja) 2013-12-25 2019-12-04 Jcrファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
PL3092251T3 (pl) 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
CA2943890A1 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
EP3166626B1 (en) 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10068619B1 (en) 2014-07-25 2018-09-04 Western Digital Technologies, Inc. Hand held storage device
WO2016025519A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
JP2017534640A (ja) 2014-11-10 2017-11-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルファ−l−イズロニダーゼ、イズロン酸−2−スルファターゼおよびアルファガラクトシダーゼaの治療用組成物ならびにそれらの使用方法
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3253884B1 (en) 2015-02-05 2020-03-18 R.P. Scherer Technologies, LLC Activated formylglycine-generating enzymes and methods of producing and using the same
WO2016191869A1 (en) 2015-06-01 2016-12-08 The Hospital For Sick Children Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
ES2849248T3 (es) 2015-06-24 2021-08-17 Beumer Group As Clasificador de línea
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
WO2017003270A1 (ko) 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017055586A1 (en) 2015-10-01 2017-04-06 Swedish Orphan Biovitrum Ab (Publ) Modified iduronate 2-sulfatase and production thereof
JP2018535654A (ja) 2015-10-01 2018-12-06 スウェディッシュ オーファン バイオビトラム アクティエボラーグ (ペーウーベーエル) 修飾リソソームタンパク質とその製造
WO2017062666A2 (en) 2015-10-06 2017-04-13 Patricia Dickson Enzyme replacement therapy for mucopolysaccharidosis iiid
US20180221459A1 (en) 2015-10-06 2018-08-09 LA BioMedical Research Institute at Harbor-UCLA Medical Center Enzyme replacement therapy for mucopolysaccharidosis iiid
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
HK1258054A1 (zh) 2015-12-30 2019-11-01 株式会社绿十字 用於治疗亨特综合征的方法和组合物
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3419651B1 (en) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
WO2017151791A1 (en) 2016-03-01 2017-09-08 Biostrategies LC Materials and methods for mitigating immune-sensitization
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
US10169252B2 (en) 2016-07-15 2019-01-01 International Business Machines Corporation Configuring functional capabilities of a computer system
CA3033082A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
EP3556399A1 (en) 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
GB201701968D0 (en) 2017-02-07 2017-03-22 Univ Manchester Gene therapy
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
JP7106289B2 (ja) 2017-02-21 2022-07-26 Jcrファーマ株式会社 グリコサミノグリカンの分析法
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2019009884A1 (en) 2017-07-03 2019-01-10 Mark Anthony Allen VISUAL DRIVING AID FOR VEHICLE VISOR
US20200157172A1 (en) 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
KR20190013615A (ko) 2017-07-28 2019-02-11 한미약품 주식회사 이두로네이트 2-설파타제 결합체
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
WO2019049967A1 (ja) 2017-09-07 2019-03-14 Jcrファーマ株式会社 水性医薬組成物
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
BR112020013921A2 (pt) 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CA3109763A1 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
KR20200094577A (ko) 2019-01-30 2020-08-07 주식회사 모비스 인공신경망 시뮬레이터와 강화학습 제어기를 사용한 실시간 가속기 제어 시스템
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Similar Documents

Publication Publication Date Title
KR102507853B1 (ko) 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
JP5823954B2 (ja) Fgf21変異体及びその使用
JP2020508053A (ja) 操作されたポリペプチド
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
JP2017528449A (ja) アミロイドーシスのための標的化免疫療法
CN109890410A (zh) 免疫球蛋白和它的用途
BRPI0911385B1 (pt) Polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
AU2014218854A1 (en) Methods and compositions for treatment of Pompe disease
JP2014520148A (ja) 治療のための神経筋接合部への標的化
CN111886240A (zh) 血脑屏障迁移化合物及其用途
JP2025000736A (ja) Enpp1ポリペプチドおよびその使用方法
US20180055913A1 (en) Recombinant collagen iv surrogates and uses thereof
WO2014190305A2 (en) Anti-gpiib/iiia antibodies or uses thereof
CA3179834A1 (en) Ace2-fc fusion proteins and methods of use
JP2025532618A (ja) 新規なヒアルロニダーゼph-20変異体及びその使用
CA2820630A1 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
US20250136963A1 (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
JPH07506342A (ja) マトリックスアッセンブリーに対するモジュレーターであるフィブロネクチン結合部位を有するポリペプチド
JP7059003B2 (ja) 脱免疫化リゾスタフィン及び使用方法
JPH05271291A (ja) 機能性ポリペプチド
US12171802B2 (en) Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
WO2026006173A1 (en) Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof
JP5581723B2 (ja) 神経突起伸長促進剤
HK40063309A (en) Fusion proteins comprising enzyme replacement therapy enzymes